Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Diabetes

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    July 2017
  1. NGUYEN JT, Molony DA
    Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes.
    Ann Intern Med. 2017;167:JC5.
    PubMed     Text format    


  2. BARRY MJ, Humphrey LL, Qaseem A
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017;167:75-76.
    PubMed     Text format    


  3. BELL DSH
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017;167:74-75.
    PubMed     Text format    


  4. INZUCCHI SE, Kosiborod M
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017;167:73-74.
    PubMed     Text format    


  5. JACK MM
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;167:72.
    PubMed     Text format    


  6. SLAVIN J
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;167:71-72.
    PubMed     Text format    


  7. SCHILLINGER D, Kearns C
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;167:72-73.
    PubMed     Text format    


    May 2017
  8. RUSHAKOFF RJ, Sullivan MM, MacMaster HW, Shah AD, et al
    Association Between a Virtual Glucose Management Service and Glycemic Control in Hospitalized Adult Patients: An Observational Study.
    Ann Intern Med. 2017;166:621-627.
    PubMed     Text format     Abstract available


    April 2017
  9. JASIM S, Smith SA
    Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF.
    Ann Intern Med. 2017;166:JC46.
    PubMed     Text format    


  10. RODRIGUEZ-GUTIERREZ R, Montori VM
    Guideline: In type 2 diabetes, ACP recommends metformin monotherapy if drugs are needed for glycemic control.
    Ann Intern Med. 2017;166:JC39.
    PubMed     Text format    


  11. PETERSEN MP, Ratner RE
    Should We Screen for Type 2 Diabetes?
    Ann Intern Med. 2017;166:535.
    PubMed     Text format    


  12. RIND DM
    Should We Screen for Type 2 Diabetes?
    Ann Intern Med. 2017;166:535-536.
    PubMed     Text format    


    March 2017
  13. CHAMBERLAIN JJ, Herman WH, Leal S, Rhinehart AS, et al
    Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Mar 14. doi: 10.7326/M16-2937.
    PubMed     Text format     Abstract available


    February 2017
  14. BACH RG
    Review: Long-term dual-antiplatelet therapy (DAPT) after PCI is no better than short-term DAPT, even with diabetes.
    Ann Intern Med. 2017;166:JC22.
    PubMed     Text format    



  15. Correction: Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;166:232.
    PubMed     Text format    


    January 2017
  16. DONATO AA
    Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;166:JC8.
    PubMed     Text format    


  17. BROPHY J
    Review: In type 2 diabetes, sodium-glucose cotransporter 2 inhibitors do not increase major CV events or mortality.
    Ann Intern Med. 2017;166:JC7.
    PubMed     Text format    


  18. QASEEM A, Barry MJ, Humphrey LL, Forciea MA, et al
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
    Ann Intern Med. 2017 Jan 3. doi: 10.7326/M16-1860.
    PubMed     Text format     Abstract available



  19. Oral Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2017 Jan 3. doi: 10.7326/P16-9028.
    PubMed     Text format    


  20. FRADKIN JE, Rodgers GP
    Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind.
    Ann Intern Med. 2017 Jan 3. doi: 10.7326/M16-2883.
    PubMed     Text format    


    December 2016
  21. TANNER M
    In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.
    Ann Intern Med. 2016;165:JC64.
    PubMed     Text format    


  22. PETERSON KA
    Balancing Primary Diabetes Care Quality and Services.
    Ann Intern Med. 2016 Dec 13. doi: 10.7326/M16-2768.
    PubMed     Text format    


  23. CHEUNG A, Stukel TA, Alter DA, Glazier RH, et al
    Primary Care Physician Volume and Quality of Diabetes Care: A Population-Based Cohort Study.
    Ann Intern Med. 2016 Dec 13. doi: 10.7326/M16-1056.
    PubMed     Text format     Abstract available


    November 2016
  24. MURFF HJ
    Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo.
    Ann Intern Med. 2016;165:JC53.
    PubMed     Text format    


  25. SCHILLINGER D, Tran J, Mangurian C, Kearns C, et al
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes? Industry and the Manufacture of Scientific Controversy.
    Ann Intern Med. 2016 Nov 1. doi: 10.7326/L16-0534.
    PubMed     Text format    


    October 2016
  26. GONZALES K, Gandhi GY
    In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.
    Ann Intern Med. 2016;165:JC40.
    PubMed     Text format    


  27. PATEL T
    In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y.
    Ann Intern Med. 2016;165:JC39.
    PubMed     Text format    


  28. MAZUREK M, Lip GY
    In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
    Ann Intern Med. 2016;165:JC38.
    PubMed     Text format    


  29. SMETANA GW, Abrahamson MJ, Rind DM
    Should We Screen for Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2016;165:509-516.
    PubMed     Text format     Abstract available


    September 2016
  30. STEINBERG DI
    Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients.
    Ann Intern Med. 2016;165:JC33.
    PubMed     Text format    


    August 2016
  31. TANNER M
    Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia.
    Ann Intern Med. 2016;165:JC20.
    PubMed     Text format    


  32. GUNDERSON EP
    Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus.
    Ann Intern Med. 2016;165:299-300.
    PubMed     Text format    


  33. NAGAHORI W, Takenoshita H, Yuki K, Kimachi M, et al
    Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus.
    Ann Intern Med. 2016;165:299.
    PubMed     Text format    


  34. LOPEZ D, Luque-Fernandez MA, Steele A, Adler GK, et al
    "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study.
    Ann Intern Med. 2016 Aug 2. doi: 10.7326/M16-0547.
    PubMed     Text format     Abstract available


  35. SIU AL
    Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus.
    Ann Intern Med. 2016;165:225.
    PubMed     Text format    


  36. BARKOUDAH E, Weinrauch LA
    Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus.
    Ann Intern Med. 2016;165:225.
    PubMed     Text format    



  37. Assessing the Risk for Diabetes in Patients With Unexpectedly Identified Tumors in the Adrenal Glands.
    Ann Intern Med. 2016 Aug 2. doi: 10.7326/P16-9020.
    PubMed     Text format    


    July 2016
  38. SFEIR JG, Montori VM
    In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis.
    Ann Intern Med. 2016;165:JC2.
    PubMed     Text format    


  39. ALI MK, Singh K, Kondal D, Devarajan R, et al
    Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals: A Randomized, Controlled Trial.
    Ann Intern Med. 2016 Jul 12. doi: 10.7326/M15-2807.
    PubMed     Text format     Abstract available


  40. BRAILLON A
    Moderate Alcohol Intake and Cardiometabolic Risk in Adults With Type 2 Diabetes.
    Ann Intern Med. 2016;165:68.
    PubMed     Text format    


  41. ALTMAN DG
    Moderate Alcohol Intake and Cardiometabolic Risk in Adults With Type 2 Diabetes.
    Ann Intern Med. 2016;165:67-8.
    PubMed     Text format    


  42. SAITZ R, Naimi T
    Moderate Alcohol Intake and Cardiometabolic Risk in Adults With Type 2 Diabetes.
    Ann Intern Med. 2016;165:67.
    PubMed     Text format    


    June 2016
  43. MANTILLA LL, Montori VM
    Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more.
    Ann Intern Med. 2016;164:JC62.
    PubMed     Text format    



  44. Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
    Ann Intern Med. 2016 Jun 21. doi: 10.7326/P16-9018.
    PubMed     Text format    


  45. VILAR-GOMEZ E, Adams LA
    Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?
    Ann Intern Med. 2016 Jun 21. doi: 10.7326/M16-1303.
    PubMed     Text format    


  46. CUSI K, Orsak B, Bril F, Lomonaco R, et al
    Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Ann Intern Med. 2016 Jun 21. doi: 10.7326/M15-1774.
    PubMed     Text format     Abstract available


    April 2016
  47. MOREIRA AM, Londero TM, Goemann IM, Schaan BD, et al
    Cardiometabolic Effects of CASCADE Trial Explained by Mediterranean Diet.
    Ann Intern Med. 2016;164:573-4.
    PubMed     Text format    


    March 2016
  48. FREUND T, Peters-Klimm F, Boyd CM, Mahler C, et al
    Medical Assistant-Based Care Management for High-Risk Patients in Small Primary Care Practices: A Cluster Randomized Clinical Trial.
    Ann Intern Med. 2016;164:323-30.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: